Cargando…
Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be very different from that of hepatocellular carcinoma. We present a case of FLC in a patient in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743402/ https://www.ncbi.nlm.nih.gov/pubmed/36600603 http://dx.doi.org/10.1136/jitc-2022-005620 |
_version_ | 1784848719274835968 |
---|---|
author | Berger, Raanan Dinstag, Gal Tirosh, Omer Schiff, Eyal Kleiner, David Aldape, Kenneth D Ruppin, Eytan Beker, Tuvik Kurzrock, Razelle |
author_facet | Berger, Raanan Dinstag, Gal Tirosh, Omer Schiff, Eyal Kleiner, David Aldape, Kenneth D Ruppin, Eytan Beker, Tuvik Kurzrock, Razelle |
author_sort | Berger, Raanan |
collection | PubMed |
description | Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be very different from that of hepatocellular carcinoma. We present a case of FLC in a patient in her mid 30s that recurred and persisted despite resection and multiple lines of treatment. Following transcriptomic analysis, a combination of ipilimumab (anti-CTLA4) and nivolumab (anti-PD-1) led to complete remission, although common biomarkers for immune checkpoint blockade were all negative in this case. The patient is still in remission. Here, combined checkpoint blockade guided by novel transcriptomic analysis led to complete remission after failure of several lines of treatment. |
format | Online Article Text |
id | pubmed-9743402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-97434022022-12-13 Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab Berger, Raanan Dinstag, Gal Tirosh, Omer Schiff, Eyal Kleiner, David Aldape, Kenneth D Ruppin, Eytan Beker, Tuvik Kurzrock, Razelle J Immunother Cancer Case Report Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be very different from that of hepatocellular carcinoma. We present a case of FLC in a patient in her mid 30s that recurred and persisted despite resection and multiple lines of treatment. Following transcriptomic analysis, a combination of ipilimumab (anti-CTLA4) and nivolumab (anti-PD-1) led to complete remission, although common biomarkers for immune checkpoint blockade were all negative in this case. The patient is still in remission. Here, combined checkpoint blockade guided by novel transcriptomic analysis led to complete remission after failure of several lines of treatment. BMJ Publishing Group 2022-12-09 /pmc/articles/PMC9743402/ /pubmed/36600603 http://dx.doi.org/10.1136/jitc-2022-005620 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Case Report Berger, Raanan Dinstag, Gal Tirosh, Omer Schiff, Eyal Kleiner, David Aldape, Kenneth D Ruppin, Eytan Beker, Tuvik Kurzrock, Razelle Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab |
title | Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab |
title_full | Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab |
title_fullStr | Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab |
title_full_unstemmed | Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab |
title_short | Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab |
title_sort | fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743402/ https://www.ncbi.nlm.nih.gov/pubmed/36600603 http://dx.doi.org/10.1136/jitc-2022-005620 |
work_keys_str_mv | AT bergerraanan fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab AT dinstaggal fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab AT tiroshomer fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab AT schiffeyal fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab AT kleinerdavid fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab AT aldapekennethd fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab AT ruppineytan fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab AT bekertuvik fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab AT kurzrockrazelle fibrolamellarcarcinomatranscriptomicbasedtreatmentpredictioncompleteresponseafternivolumabandipilimumab |